David F Bruhn1, Susan Wyllie2, Adaris Rodríguez-Cortés3, Angela K Carrillo3, R Kiplin Guy3, Alan H Fairlamb2, Richard E Lee4. 1. Department of Chemical Biology and Therapeutics, St Jude Children's Research Hospital, Memphis, TN, USA Avista Pharma Solutions, Durham, NC, USA. 2. Division of Biological Chemistry and Drug Discovery, Wellcome Trust Biocentre, College of Life Sciences, University of Dundee, Dundee, Scotland, UK. 3. Department of Chemical Biology and Therapeutics, St Jude Children's Research Hospital, Memphis, TN, USA. 4. Department of Chemical Biology and Therapeutics, St Jude Children's Research Hospital, Memphis, TN, USA richard.lee@stjude.org.
Abstract
OBJECTIVES: In response to reports of Trypanosoma brucei resistance to the nitroaromatic drug nifurtimox, we evaluated the potential of antituberculosis nitrofuran isoxazolines as inhibitors of trypanosome growth. METHODS: The susceptibility of T. brucei brucei was assessed in vitro. The lowest effective concentration to inhibit growth (EC90) against drug-susceptible and -resistant parasites, time-kill kinetics, reversibility of inhibition and propensity for P-glycoprotein-mediated exclusion from the blood-brain barrier were determined. RESULTS: Nitrofuran isoxazolines were potent inhibitors of T. brucei brucei proliferation at nanomolar concentrations, with pentacyclic nitrofurans being 100-fold more potent than nifurtimox. Activity was sustained against nifurtimox-resistant parasites, suggesting the possibility of a unique mechanism of activation and potential for use in the treatment of drug-resistant infections. Exposure of parasites to the maximum concentrations of Compound 15 achieved in vivo with oral dosing yielded >2 logs of irreversible killing in <4 h, indicating rapid trypanocidal activity. CONCLUSIONS: Pentacyclic nitrofuran isoxazolines warrant further development for the treatment of drug-susceptible and nifurtimox-resistant trypanosome infections.
OBJECTIVES: In response to reports of Trypanosoma brucei resistance to the nitroaromatic drug nifurtimox, we evaluated the potential of antituberculosis nitrofuran isoxazolines as inhibitors of trypanosome growth. METHODS: The susceptibility of T. brucei brucei was assessed in vitro. The lowest effective concentration to inhibit growth (EC90) against drug-susceptible and -resistant parasites, time-kill kinetics, reversibility of inhibition and propensity for P-glycoprotein-mediated exclusion from the blood-brain barrier were determined. RESULTS:Nitrofuran isoxazolines were potent inhibitors of T. brucei brucei proliferation at nanomolar concentrations, with pentacyclic nitrofurans being 100-fold more potent than nifurtimox. Activity was sustained against nifurtimox-resistant parasites, suggesting the possibility of a unique mechanism of activation and potential for use in the treatment of drug-resistant infections. Exposure of parasites to the maximum concentrations of Compound 15 achieved in vivo with oral dosing yielded >2 logs of irreversible killing in <4 h, indicating rapid trypanocidal activity. CONCLUSIONS:Pentacyclic nitrofuran isoxazolines warrant further development for the treatment of drug-susceptible and nifurtimox-resistant trypanosome infections.
Authors: Ken Stuart; Reto Brun; Simon Croft; Alan Fairlamb; Ricardo E Gürtler; Jim McKerrow; Steve Reed; Rick Tarleton Journal: J Clin Invest Date: 2008-04 Impact factor: 14.808
Authors: Shane R Wilkinson; Martin C Taylor; David Horn; John M Kelly; Ian Cheeseman Journal: Proc Natl Acad Sci U S A Date: 2008-03-26 Impact factor: 11.205
Authors: E L Vansterkenburg; I Coppens; J Wilting; O J Bos; M J Fischer; L H Janssen; F R Opperdoes Journal: Acta Trop Date: 1993-09 Impact factor: 3.112
Authors: Gary Sisson; Avery Goodwin; Ausra Raudonikiene; Nicky J Hughes; Asish K Mukhopadhyay; Douglas E Berg; Paul S Hoffman Journal: Antimicrob Agents Chemother Date: 2002-07 Impact factor: 5.191